Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 114400.0
(-4.75%)
KRW 114400.0
(-4.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.54 Billion KRW | -10.58% |
| 2022 | 19.36 Billion KRW | 336.53% |
| 2021 | -10.91 Billion KRW | -181.51% |
| 2020 | 23.9 Billion KRW | -65.39% |
| 2019 | 26.62 Billion KRW | 47.05% |
| 2018 | 20.99 Billion KRW | -29.58% |
| 2017 | 30.52 Billion KRW | -1.53% |
| 2016 | 28.13 Billion KRW | 18.89% |
| 2015 | 25.19 Billion KRW | 8.55% |
| 2014 | 23.02 Billion KRW | 15.3% |
| 2013 | 19.96 Billion KRW | 156.72% |
| 2012 | 7.77 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.43 Billion KRW | 21.34% |
| 2024 Q1 | 3.92 Billion KRW | -21.15% |
| 2023 Q3 | 4.41 Billion KRW | -18.17% |
| 2023 Q4 | 4.16 Billion KRW | -5.69% |
| 2023 FY | - KRW | -10.58% |
| 2023 Q1 | 4.01 Billion KRW | -0.99% |
| 2023 Q2 | 5.39 Billion KRW | 34.49% |
| 2022 FY | - KRW | 336.53% |
| 2022 Q1 | 5.25 Billion KRW | 235.78% |
| 2022 Q2 | 5.19 Billion KRW | -1.15% |
| 2022 Q3 | 5.72 Billion KRW | 10.24% |
| 2022 Q4 | 4.05 Billion KRW | -29.18% |
| 2021 Q3 | -7.21 Billion KRW | -118890.32% |
| 2021 Q1 | -2.9 Billion KRW | -210.84% |
| 2021 Q2 | 6.07 Million KRW | 100.21% |
| 2021 Q4 | 1.56 Billion KRW | 121.68% |
| 2021 FY | - KRW | -181.51% |
| 2020 Q2 | 5.38 Billion KRW | -3.03% |
| 2020 FY | - KRW | -65.39% |
| 2020 Q4 | -934.65 Million KRW | -195.02% |
| 2020 Q3 | 983.67 Million KRW | -81.74% |
| 2020 Q1 | 5.55 Billion KRW | 380.38% |
| 2019 Q2 | 10.11 Billion KRW | 21.11% |
| 2019 Q1 | 8.35 Billion KRW | 517.17% |
| 2019 FY | - KRW | 47.05% |
| 2019 Q4 | 1.15 Billion KRW | -90.42% |
| 2019 Q3 | 12.07 Billion KRW | 19.38% |
| 2018 Q2 | 8.7 Billion KRW | 20.67% |
| 2018 Q3 | 7.88 Billion KRW | -9.44% |
| 2018 Q4 | -2 Billion KRW | -125.4% |
| 2018 FY | - KRW | -29.58% |
| 2018 Q1 | 7.21 Billion KRW | 20.79% |
| 2017 Q1 | 8.58 Billion KRW | 13.34% |
| 2017 FY | - KRW | -1.53% |
| 2017 Q4 | 5.97 Billion KRW | -35.59% |
| 2017 Q2 | 6.38 Billion KRW | -25.61% |
| 2017 Q3 | 9.27 Billion KRW | 45.2% |
| 2016 FY | - KRW | 18.89% |
| 2016 Q3 | 7.65 Billion KRW | 1.58% |
| 2016 Q4 | 7.57 Billion KRW | -1.03% |
| 2016 Q2 | 7.53 Billion KRW | 8.43% |
| 2016 Q1 | 6.94 Billion KRW | 4.47% |
| 2015 FY | - KRW | 8.55% |
| 2015 Q3 | 6.86 Billion KRW | 19.83% |
| 2015 Q4 | 6.65 Billion KRW | -3.15% |
| 2015 Q2 | 5.73 Billion KRW | -0.17% |
| 2015 Q1 | 5.74 Billion KRW | 6.54% |
| 2014 Q2 | 5.57 Billion KRW | -10.81% |
| 2014 Q1 | 6.25 Billion KRW | 27.4% |
| 2014 FY | - KRW | 15.3% |
| 2014 Q4 | 5.38 Billion KRW | -7.2% |
| 2014 Q3 | 5.8 Billion KRW | 4.15% |
| 2013 Q2 | 4.81 Billion KRW | 8.18% |
| 2013 Q3 | 5.8 Billion KRW | 20.56% |
| 2013 Q1 | 4.44 Billion KRW | 0.0% |
| 2013 Q4 | 4.9 Billion KRW | -15.41% |
| 2013 FY | - KRW | 156.72% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | -12.74 Billion KRW | 151.367% |
| ST Pharm Co.,Ltd. | 52.48 Billion KRW | 87.523% |
| ABL Bio Inc. | 2.1 Billion KRW | -211.176% |
| Cellid, Co., Ltd. | -7.68 Billion KRW | 185.232% |